Resources

Search Tools

Covid-19 Related Resources:

Disease-Related Resources:

Cardiology

Gastrointestinal System:

Hypertension:

Neurological Disorders:

 Oncology:

Reproduction

Genetic Editing
Overcoming Infertility from Chemotherapy
Uterus Transplantation
Male Birth Control

Textbooks:

Pathophysiology

  • Porth CM. Essentials of Pathophysiology. 2015 (4th Ed). Wolters Kluwer: Philadelphia, PA. ISBN-13: 978-1-4511-9080-9 OSU eBook
  • Klaassen, C.D., Ed.: Casarett and Doull’s Toxicology: The Basic Science of Poisons.  8th Edition, McGraw-Hill, (2013) eBook

Toxicology

  • Nelson, L., & Goldfrank, L. R. (2011). Goldfrank’s toxicologic emergencies. New York: McGraw-Hill Medical. eBook
  • Rosenbaum, Sara E. Basic Pharmacokinetics and Pharmacodynamics: An Integrated Textbook and Computer Simulations. Wiley, 450 p. 2011. eISBN 9781118001059 eBook

Pharmacodynamic/Pharmacokinetics:

  • Kwon, Younggil. Handbook of essential pharmacokinetics, pharmacodynamics and drug metabolism for industrial scientists. New York: Kluwer. 2002. ISBN 9780306462344 eBook
  • Arthur J. Atkinson, Jr., Shiew‐Mei Huang, Juan J.L. Lertora and Sanford P. Markey. 3rd Principles of Clinical Pharmacology. San Diego: Academic Press. 2012. ISBN: 978‐0‐12‐385471‐1 eBook
  • Spruill, William J., Wade, William E., DiPiro, Joseph T, Blouin, Robert A., Pruemer, Jane M. Concepts in clinical pharmacokinetics (6th Edition). American Society of Health‐System Pharmacists. 2014. ISBN: 978‐1‐58528‐387‐3 eBook
  • Macheras, Panos and Iliadis, Athanassios. Modeling in biopharmaceutics, pharmacokinetics, and pharmacodynamics: Homogeneous and Heterogeneous Approaches. Springer New York. 2006. ISBN‐13: 978‐0387‐28178‐ eBook

Safety Pharmacology

  • Guyton and Hall textbook of Medical Physiology, 13th Edition, John E. Hall, PhD, 2016
  • Principles of Safety Pharmacology (Handbook of Experimental Pharmacology), Michael K. Pugsley and Michael Curtis, Editors, 2015
  • Nonclinical Assessment of Abuse Potential for New Pharmaceuticals, Carrie Markgraf, Thomas Hudzik, and David Compton, Editors, 2015
  • Electrocardiography of Laboratory Animals, Jeffrey W. Richig and Meg M. Sleeper, 2013
  • Textbook of Veterinary Internal Medicine, Stephen Ettinger and Edward C. Feldman, 7th Edition (earlier editions may not have the same chapters)
    • Chapters on Electrocardiographic Techniques; Echocardiography; Syncope; Pathophysiology of Heart Failure; Electrocardiography and Cardiac Arrhythmias; Neurologic Examination and Neuroanatomic Diagnosis; Vestibular Disease; and Clinical Approach and Laboratory Evaluation of Renal Disease

Post-Marketing Surveillance

  • Gad, Shayne C. Safety Pharmacology in Pharmaceutical Development: Approval and Post Marketing Surveillance (2nd Edition). London, GBR: CRC Press, 2012. ISBN‐13: 978‐1‐4398‐4568‐ eBook

Scientific Journals

  • Journal of Pharmacological & Toxicological Methods
  • Regulatory Toxicology and Pharmacology
  • British Journal of Pharmacology
  • Journal of Cardiovascular Pharmacology
  • Journal of Applied Toxicology
  • Cardiovascular Toxicology
  • Expert Opinion on Drug Safety
  • Toxicology and Applied Pharmacology
  • Fundamental and Clinical Pharmacology

Regulatory guidelines

  • Anon. (2000). ICHS7A: Safety pharmacology studies for human pharmaceuticals. CPMP/ICH/539/00. London. www.emea.eu.int/pdfs/human/ich/053900en.pdf
  • Anon. (2005). HHS. International Conference on Harmonisation; guidance on S7B Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals; availability. Notice. Fed Regist. 70(202):61133-4.
    http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm129122.pdf
  • Anon. (1997). Committee for Proprietary Medicinal Products (CPMP) Points to Consider: The assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products. CPMP/986/96. www.ganimed.biz/bibliothek/media/EMEA_CPMP_Dec1997.pdf
  • Anon. (2005). Clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs (E14). http://www.fda.gov/cber/gdlns/iche14qtc.pdf
  • Anon. (2010). Guidance for Industry Assessment of Abuse Potential of Drugs. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM198650.pdf
  • Anon. (2011). ICH S6: Preclinical safety evaluation of biotechnology-derived pharmaceuticals. CPMP/ICH/302/95. (Revised version (R1) finalised June 2011.).
    http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM194490.pdf
  • Anon. (2009). ICH M3(R2): Guidance on non-clinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Multidisciplinary/M3_R2/Step4/M3_R2__Guideline.pdf
  • Anon. (2005). ICH S5(R2): Detection of toxicity to reproduction for medicinal products and toxicity to male fertility. www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S5_R2/Step4/S5_R2__Guideline.pdf
  • Anon. (2006). Food and Drug Administration. Guidance for Industry: Nonclinical Safety Evaluation of Pediatric Drug Products. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm079247.pdf
  • Anon. (2008). Committee for Human Medicinal Products (CHMP). Guideline on the need for non-clinical testing in juvenile animals of pharmaceuticals for paediatric indications. EMEA/CHMP/SWP/169215/2005. www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003305.pdf
  • Anon. (2008). OECD: Guidance document on mammalian reproductive toxicity testing and assessment. ENV/JM/MONO(2008)16. www.oecd.org/officialdocuments/displaydocumentpdf/?cote=env/jm/mono(2008)16&doclanguage=en
  • Anon. (2008). Food and Drug Administration. Guidance for industry. Diabetes mellitus – evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071627.pdf
  • Anon. (2006). FDA Guidance for Industry, Investigators and Reviewers: Exploratory IND Studies. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM078933.pdf?utm_campaign=Google2&utm_source=fdaSearch&utm_medium=website&utm_term=exploratory IND&utm_content=1
  • Anon. (2009). Nonclinical evaluation for anticancer pharmaceuticals. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S9/Step4/S9_Step4_Guideline.pdf
  • Anon. (1995). Guidance for Industry Toxicokinetics: The Assessment of Systemic Exposure in Toxicity Studies (1995). http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm074937.pdf